



Ref. No.: LIC/SE/2024-25/100

Date: September 13, 2024

To  
The Manager,  
Listing Department,  
The National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor, Plot C/1,  
G Block, Bandra Kurla Complex,  
Mumbai-400051  
**Scrip Code: LICI**

Dear Sir/Madam,

**Sub: Corrigendum to Disclosure vide Ref. no. LIC/SE/2024-25/98 dated September 13, 2024**

In continuation to our earlier filing vide Ref. no. LIC/SE/2024-25/98 dated September 13, 2024 with National Stock Exchange of India Limited.

It is to inform that under Point no. 6 of Annexure-A of the above-mentioned filing, the word “increase” shall be read as “decrease”. The revised Annexure-A is enclosed herewith.

Please take the above information on record and arrange for its dissemination. A copy of this intimation is also being made available on the website of the Corporation at [www.licindia.in](http://www.licindia.in).

Yours faithfully,

**For Life Insurance Corporation of India**

**(Anshul Kumar Singh)**  
**Company Secretary & Compliance Officer**

Encl.: a/a

## Annexure-A

SL No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	AUROBINDO PHARMA LTD. Market Cap – INR 91,582.20 Cr.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No
3	Industry to which the entity being acquired belongs	Pharmaceuticals
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Investment Function. In ordinary Course of transaction.
5	Brief details of any governmental or regulatory approvals required for the acquisition	NIL
6	Indicative time period for completion of the acquisition.	There is a net decrease of 2.745% in holding during the period from 25.11.2021 - 12.09.2024
7	Date & Time of occurrence of the aforesaid event/information	13 <sup>th</sup> September 2024 at 05:57:42 AM
8	Nature of consideration - whether cash consideration or share swap and details of the same	Open Market Sale
9	Cost of acquisition/disposal or the price at which the shares are acquired;	Holding decreased from 5.01% to 2.265%, a net decrease of 2.745% during the period from 25.11.2021 to 12.09.2024 at an average cost of INR 1187.231
10	Percentage of shareholding / control acquired and / or number of shares acquired;	2.265%
11	Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.



EXECUTIVE DIRECTOR (INVT/BACKOFFICE)